REVIEW  TRENDS AND TREATMENTS IN VENA CAVA DISEASE Free access

The Journal of Cardiovascular Surgery 2022 December;63(6):674-81

DOI: 10.23736/S0021-9509.22.12448-1

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Interventions for superior vena cava syndrome

Indrani SEN ✉, Manju KALRA, Peter GLOVICZKI

Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN, USA

Superior vena cava (SVC) syndrome refers to the clinical manifestations of cerebral venous hypertension secondary to obstruction of the SVC and/or the innominate veins. The most common cause of SVC syndrome is malignancy like small cell lung cancer and non-Hodgkin lymphoma, but there is an increasing trend of benign etiologies secondary to thrombosis due to central lines/ pacemakers or mediastinal fibrosis. Supportive measures include head elevation, diuresis, supplemental oxygen, and steroids. Thrombolysis with or without endovenous stenting is required emergently in those with airway compromise or symptoms secondary to cerebral edema. Definitive treatment in those with malignancy is multidisciplinary; this requires radiotherapy, chemotherapy, SVC stenting, oncologic surgery and SVC bypass or reconstruction. Endovascular treatment is the primary modality for palliation in malignancy and in those with benign etiology. Surgery is reserved for those who have failed or are unsuitable for endovascular treatment. In patients with benign disease endovenous stenting and open surgery provide excellent symptom relief and are safe and effective.

KEY WORDS: Vena cava, superior; Stents; Endovascular procedures